- Home
- MIST vs SGMO Comparison
MIST vs SGMO Comparison
Compare MIST & SGMO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MIST
- SGMO
- Stock Information
- Founded
- MIST 2003
- SGMO 1995
- Country
- MIST Canada
- SGMO United States
- Employees
- MIST N/A
- SGMO N/A
- Industry
- MIST Biotechnology: Pharmaceutical Preparations
- SGMO Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- MIST Health Care
- SGMO Health Care
- Exchange
- MIST Nasdaq
- SGMO Nasdaq
- Market Cap
- MIST 132.5M
- SGMO 122.8M
- IPO Year
- MIST N/A
- SGMO 2000
- Fundamental
- Price
- MIST $1.43
- SGMO $0.56
- Analyst Decision
- MIST Strong Buy
- SGMO Buy
- Analyst Count
- MIST 2
- SGMO 6
- Target Price
- MIST $7.50
- SGMO $4.50
- AVG Volume (30 Days)
- MIST 2.9M
- SGMO 5.9M
- Earning Date
- MIST 08-15-2025
- SGMO 08-12-2025
- Dividend Yield
- MIST N/A
- SGMO N/A
- EPS Growth
- MIST N/A
- SGMO N/A
- EPS
- MIST N/A
- SGMO N/A
- Revenue
- MIST N/A
- SGMO $63,756,000.00
- Revenue This Year
- MIST N/A
- SGMO $1.29
- Revenue Next Year
- MIST N/A
- SGMO $1.60
- P/E Ratio
- MIST N/A
- SGMO N/A
- Revenue Growth
- MIST N/A
- SGMO 239.92
- 52 Week Low
- MIST $0.63
- SGMO $0.41
- 52 Week High
- MIST $2.75
- SGMO $3.18
- Technical
- Relative Strength Index (RSI)
- MIST 40.51
- SGMO 54.90
- Support Level
- MIST $1.42
- SGMO $0.50
- Resistance Level
- MIST $1.64
- SGMO $0.70
- Average True Range (ATR)
- MIST 0.11
- SGMO 0.05
- MACD
- MIST -0.03
- SGMO 0.00
- Stochastic Oscillator
- MIST 8.95
- SGMO 39.83
About MIST Milestone Pharmaceuticals Inc.
Milestone Pharmaceuticals Inc is a biopharmaceutical company dedicated to developing and commercializing etripamil for the treatment of cardiovascular medicines. Etripamil is a calcium channel blocker developed as a rapid-onset nasal spray to be administered by the patient to treat episodes of paroxysmal supraventricular tachycardia, or PSVT. The company has an ongoing Phase 2 clinical trial for patients with atrial fibrillation experiencing a rapid ventricular rate (AFib-RVR).
About SGMO Sangamo Therapeutics Inc.
Sangamo Therapeutics Inc is a genomic medicine company committed to translating ground-breaking science into medicines that transform the lives of patients and families afflicted with serious neurological diseases. Its pipeline products include the Priority Neurology Pipeline offers Chronic Neuropathic Pain, Prion Disease, and Neurology; Partnered Programs offer Hemophilia A, Oncology, ALS/FTD, and Huntington's Disease; and Other Pipelines include Fabry Disease, Renal Transplant, Inflammatory Bowel Disease, and Multiple Sclerosis.